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Summary Previous studies have shown that sera from patients with pancreatic cancer often contain a mucus
glycoprotein that expresses the oncofetal antigen galactose 1-3, N-acetyl galactosamine, which is the T blood
group antigen and the binding site for the lectin peanut agglutinin (PNA). An enzyme-linked lectin assay has
been developed to quantify PNA-binding glycoproteins in serum and has been evaluated as a serological test
for pancreatic cancer. Sera were studied from 53 patients with pancreatic cancer and 154 controls, including
benign obstructive jaundice, acute and chronic pancreatitis, chronic liver disease and inflammatory bowel
disease. The enzyme-linked peanut lectin assay proved highly reproducible and has 77% sensitivity and 83%
specificity for pancreatic cancer, results that are very similar to those achieved in the same sera by CA19-9
radioimmunoassay (75% sensitivity, 82% specificity with the upper limit of normal set at 37uml-1). CEA
assay pro.ved less useful (60% sensitivity, 47% specificity). In this study better results were obtained if an
upper limit of normal of 50uml-1 was used for CAl9-9 (75% sensitivity, 92% specificity). Combination of
CA19-9 assay with the upper limit set at 50uml-i and the peanut lectin assay improved the sensitivity to
85% with only a slight fall in specificity (85%). These results compare well with published results for
ultrasound and CT scanning.
Pancreatic cancer can be notoriously difficult to diagnose,
particularly in the non-jaundiced patient, and there is a need
for better and simpler diagnostic tests which might allow the
diagnosis to be made or excluded without recourse to more
invasive tests. Symptomatic pancreatic cancer is sadly almost
always incurable and if a high degree of diagnostic accuracy
could be achieved a simple test that could be used for
screening pre-symptomatic patients could be very valuable if
some way could be found of defining a high risk population.
Several tumour associated antigens have been described in
pancreatic cancer sera. These include carcinoembryonic
antigen (CEA) (Gold & Freedman, 1965; Tatsuta et al.,
1984), pancreatic oncofetal antigen (POA) (Banwo et al.,
1974; Nishida et al., 1985), pancreatic cancer associated
antigen (PCAA) (Chu et al., 1977; Loor et al., 1984), DU-
PAN 2 (Metzgar et al., 1984; Sawaku et al., 1986), CA19-9
(Koprowski et al., 1979; Haglund et al., 1986b), CA50
(Lindholm et al., 1983; Habib et al., 1986) and CA12-5
(Lehmann et al., 1984; Haglund, 1986). The most successful
of these has proved to be CA19-9, which recognises the
sialylated blood group Lewis antigen, which is expressed on
a mucin secreted by the pancreatic tumour into the serum
(Magnani et al., 1983). However, most published studies
have shown a considerable overlap between CA19-9 serum
levels in pancreatic cancer and controls (Haglund et al.,
1986; Savarino et al., 1984; Tatsuta et al., 1985; Harmenberg
et al., 1988). It is notable that these marker proteins, like
most other tumour associated antigens, are glycoproteins
that are either present in normal tissue or differ from normal
glycoproteins in their carbohydrate rather than their protein
structure. In a previous study we therefore used a
combination of SDS-polyacrylamide gel electrophoresis and
lectin blotting with a panel of lectins (analogous to 'Western'
immunoblotting) to search for altered serum glycoproteins in
pancreatic cancer. A high molecular weight peanut lectin
binding glycoprotein was identified (molecular weight
approx. 3.5 x 106 D) in approximately one-third of pancreatic
cancer sera and none of 80 controls (Ching & Rhodes, 1988).
In some but not all cases CA19-9 also bound to this
glycoprotein, which further studies confirmed as a mucin. It
seems likely that this mucin has the potential to bear several
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carbohydrate epitopes along its length including the
sialylated Lewis antigen (CA19-9 binding) and T antigen
(galactose 1-3, N-acetyl galactosamine, peanut agglutinin
binding). In some pancreatic cancer sera, lectin blotting
studies showed that this mucin accounted for a high
proportion of the total peanut lectin binding glycoproteins in
serum. It therefore seemed worthwhile to develop an
enzyme-linked lectin assay (ELLA) for total peanut lectin
binding glycoproteins in serum, partly because this was likely
to be more sensitive and easier to perform than lectin
blotting and also because results of the blotting experiments
suggested that assay of peanut binding glycoprotein might
complement CA19-9 assay and thus improve the sensitivity
of serological testing for pancreatic cancer.
Materials and methods
Materials
Sera were studied from 53 patients with pancreatic cancer
(mean age 63, range 36-85, 27 males and 26 female) of
whom 31 had obstructive jaundice. Forty-one were
histologically confirmed and the remainder diagnosed
radiologically. Twenty-eight had sufficient information for
TNM staging. Controls included other cancers (n=27, 13
colorectal, 9 gastric, 1 breast, 2 bronchial and 2
hepatocellular carcinoma), pancreatitis (n =23, 15 chronic
and 8 acute), benign obstructive jaundice due to
cholelithiasis (n=36) and malignant obstructive jaundice due
to hepatocellular carcinoma, hilar cholangiocarcinoma or
ampullary carcinoma (n=14), inflammatory bowel disease
(n=15), chronic liver disease (n=24) and normals (n=29,
mean age 28, range 18-48, 14 male and 15 female). Sera
were obtained and stored at -70°C until studied. Micro-
ELISA plates (M124B) were obtained from Dynatech, FRG,
peroxidase-tagged PNA from Sigma, USA, and CA19-9 RIA
and CEA RIA kits from CIS, UK.
Enzyme-linked lectin assay (PNA-ELLA)
Checkerboard studies Checkerboard studies were performed
to assess optimal concentrations of test sera and lectin for
use in the assay. They were performed according to McCoy
et al. (1983) with some modifications. Serial dilution from
1:2,000 to 1:256,000 of a pancreatic cancer serum known to
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contain the high molecular weight abnormal glycoprotein
was performed and 100,lp of these diluted samples applied in
duplicate to coat micro-ELISA plates for 16h at 4°C. The
plates were then washed and quenched in PBS/Tween 20
(0.1%) buffer for 1 h at room temperature followed by
incubation with three different concentrations of peroxidase-
tagged PNA lectin (12.5Sgrmn-1, 6.25pgml-1 and
3.125pgml-1) for each set of the serially diluted samples.
Unbound lectins were removed by washing with PBS/Tween
20 buffer three times after 16h incubation at 4°C. Peroxidase
activity was detected by a combination of 0-
phenylenediamine (10mg) and H202 (40pl) in phosphate
citrate buffer (25ml, pH 5.0). Reaction was allowed to
proceed for 10min at room temperature and then terminated
by addition of 4M H2SO4. Optical density was read at
492nm using a standard micro-ELISA reader (CLS, 962
microplate reader, Cambridge, UK).
Results obtained using 12.5pgml 1 peroxidase-PNA were
shown to be optimal (Figure 1). At this concentration,
1:20,000 dilution of the positive control serum gave on o.d.
of 1.0. Subsequent experiments were carried out using
1:20,000 dilution of sera and 12.5pgml 1 peroxidase-PNA.
Determination of total serum peanut lectin binding activity
(PLBA) Duplicates of Ip00 ul (1:20,000) diluted serum
samples and serially diluted positive control sera were
incubated on the ELISA plate for 16h at 4°C. Pancreatic
cancer and control sera were randomly distributed on the
ELISA plate and assayed blind. The plate was washed x 3
and quenched with PBS/Tween 20 buffer and then l00p1
peroxidase-PNA (12.5 pgml- 1) was applied in each well and
incubated at 4°C for 16h. Unbound peroxidase-PNA was
then washed off using the same buffer and bound lectin
identified using 0-phenylenediamine and H202 in phosphate
citrate buffer as described before. The o.d. of test sera was
measured and converted into units PLBA per ml with
reference to the positive control serum. The same positive
control serum from a patient with histologically proven
pancreatic cancer was used throughout all the assays. 1 unit
PLBA ml-1 was arbitrarily defined as peanut agglutinin
binding activity equivalent to a 1:20,000 dilution of this
positive control serum. The upper limit of the normal range
was taken as the value (0.6uml-1) which included 95% of
the normal sera. Intraplate and interplate variation was
assessed with the help of four additional internal standards
(two normal and two pancreatic cancer sera).
RIA CA19-9 and RIA CEA
Radioimmunoassays for CA19-9 and CEA were performed
according to the manufacturers' instructions (CIS, UK).
Standards and sera undergoing test were incubated in
polystyrene tubes pre-coated with CAI9-9 or CEA
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Figure I Results of a checkerboard experiment using serial
dilutions of a PNA binding pancreatic cancer serum and three
different concentrations of peroxidase-PNA.
antibodies. Unbound antigens were removed by repeated
( x 3) washings with either distilled water or Tween 20 buffer
followed by incubation with 1251 labelled anti-CA19-9 or
1251 anti-CEA antibodies. Unbound antibodies were
removed by further washings and radioactivity determined
using a gamma counter (minigamma, Pharmacia-LKB,
Sweden).
Statistical analysis
Statistical analysis of marker activity in advanced versus
localised disease was performed using Wilcoxon's rank sum
test.
Results
Enzyme-linked lectin assay (PNA-ELLA)
The intraplate and interplate variation were found to be
8.1% and 7.5% respectively, indicating good reproducibility
(Table I). When 0.6u PLBAml-1 is taken as the normal cut-
off limit, this assay has a sensitivity of 77% and specificity
of 83% for pancreatic cancer (malignant controls were
excluded from the latter calculation) (Figure 2). The positive
predictive value is 68% and negative predictive value 89%.
There was no apparent difference in levels of PLBA between
the jaundiced and non-jaundiced patients with pancreatic
cancer. However, patients with metastatic disease (T1 _3,
N1I2, M1) have significantly higher PLBA than those with
localised disease (T1I, N,o MO) (P<0.02) (Figure 3).
CA19-9 RIA
This assay had a sensitivity of 75% and specificity of 82%
for pancreatic cancer (malignant controls excluded) when the
normal cut-off limit was set according to the manufacturer's
recommendation at 37uml-1 (Figure 4). The positive
predictive and negative predictive values are 67 and 88%
respectively. These results are very similar to PNA-ELLA.
Patients with extensive disease similarly had significantly
higher CA19-9 levels than those with localised disease
(P<0.05) (Figure 3). If the normal cut-off limit for CAl9-9
was raised to 50uml-1 the specificity improved to 92%
without any reduction in sensitivity in this study.
CEA RIA
CEA RIA had the poorest sensitivity (60%) and specificity
(47%) for pancreatic cancer among the three assays tested
with the normal cut-off limit set at 2.5ngml-1 (Figure 5).
Normal CEA levels were found in the majority of the
normal healthy controls but many of the non-malignant
disease control sera had high CEA levels. The positive
predictive and negative predictive values were also inferior to
PNA-ELLA and CA19-9 RIA. However, CEA levels did
correlate with stage of disease (P<0.05) (Figure 3).
Combination of PNA-ELLA and Ca19.9
In this study we were unable to achieve better sensitivity for
pancreatic cancer by adjustment of normal cut-off limits in
any of these three assays without severely reducing
specificity. However, combination ofPNA-ELLA and CA19-9
RIA, with upper limits of normal set at 0.85uml-1 (PNA-
ELLA) and 50uml-1 (CA19-9) improved the sensitivity to
85% with a specificity of 85%. The addition of CEA to
these two assays only marginally increased the sensitivity
(87%) but at the expense of a considerable drop in
specificity (68%) (Table I).
Nine sera from the 27 non-jaundiced patients with other
cancers had elevated concentrations of PNA binding activity,
including seven with gastrointestinal malignancy and two
with tumours affecting other sites (breast and bronchus). The
latter two patients' sera also had elevated concentrations of
CA19-9 binding activity.ENZYME-LINKED PNA LECTIN BINDING ASSAY 951
Table I Results of PNA-ELLA, CA19-9 RIA and CEA RIA for pancreatic cancer
PNA-ELLA
PNA-ELLA CA19-9 (0.85uml-1)
PNA-ELLA CA19-9 (0.85 uml- 1) (50 uml-1 combined with
(uml- 1) (uml-1) CEA combined with combined with CEA (5ngml-1) and
(Upper limit of normal) 0.6 0.85 37 50 (2.5ngml-1) CA19-9 (50uml-1) CEA (5ngml-1) CA19-9 (50uml-1)
Sensitivity (%) 77 62 75 75 60 85 77 87
Specificity (%) 83 92 82 90 47 85 71 68
Positive predictive value (%) 68 79 67 78 35 63 55 48
Negative predictive value (%) 89 84 88 89 72 92 87 94
Efficiency (%) 81 83 80 85 51 85 73 73
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Figure 2 Results of PNA-ELLA in pancreatic cancers and
controls. 0.6 u PLBAml-1 is chosen as the upper limit of normal
(U histological diagnosis, * radiological diagnosis).
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Figure 3 Results of PNA-ELLA (0), CA19-9 RIA (A) and
CEA RIA (0) in 28 pancreatic cancer patients with known
clinical staging. TNM staging is according to Kloppel (1984).
Figure 4 Results of CA19-9 RIA in pancreatic cancer and
controls. 37uml-' is taken as the upper limit of normal (U
histological diagnosis, * radiological diagnosis).
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Figure 5 Results of CEA RIA in pancreatic cancer and
controls. 2.5 ngml-1 is taken as the upper limit of normal (-
histological diagnosis, 0 radiological diagnosis).
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Discussion
This study shows that an enzyme-linked peanut lectin
binding assay can be used to detect tumour-related
glycoproteins present in the serum of patients with
pancreatic cancer. It is reproducible and easy to perform and
has a sensitivity (77%) and specificity (82%) comparable to
that for CA19-9 radioimmunoassay.
Most of the serological tumour associated antigens so far
described have been discovered by developing monoclonal
antibodies against tumour extracts but it has become
apparent that most of these markers are heavily glycosylated
glycoproteins and in many cases the epitope for the
monoclonal antibody has proved to be a complex
carbohydrate rather than a protein. Lectins are plant or
animal glycoproteins with specificity for carbohydrates and
are proving useful tools in the detection of glycoprotein
alterations in malignant disease. Peanut agglutinin (PNA),
which binds to the exposed Thomson Friedenreich antigen
(galactose 1-3, N-acetyl galactosamine) on desialylated cell
surface and mucus glycoproteins, has probably been the
most widely used. It has been shown to bind to neoplastic
colonic (Boland et al., 1982), gastric (Martin & Wilbur,
1985), breast (Howard et al., 1981) and lymphoid (Veerman
et al., 1985) tissue with little or no binding to normal tissues
from these sites. It does, however, also bind to hyperplastic
or adenomatous colonic mucosa (Rhodes et al., 1986) so is
not totally specific for epithelial malignancy.
Lectin histochemistry of the pancreas has shown some
cytoplasmic PNA positivity even in normal tissue but in
pancreatic cancer strong PNA positive mucin is often seen
(Ching et al., 1988). CA19-9 positivity is also found in
normal pancreas (Haglund et al., 1986a) and it seems likely
from lectin and immunoblotting studies (Ching & Rhodes
1988) that the high levels of PNA and CA19-9 binding
activity in pancreatic cancer sera reflect mucin, which is
probably structurally immature, i.e. incompletely
glycosylated and sialylated, and which has been shed into the
serum. It is interesting that sera from colorectal cancer
patients less frequently contain this mucin despite the facts
that CA19-9 was originally developed against a colorectal
cancer cell line and that colorectal cancers are usually PNA
positive. It seems likely that pancreatic cancers either secrete
more mucin than colorectal cancers or invade blood vessels
more readily. Positive results with either PNA-ELLA or
CA19-9 assay clearly have to be expected in some patients
with epithelial cancers other than pancreatic cancer but
providing the clinician is aware of this it should not prove a
great problem.
Radioimmunoassay with CA19-9 has up till now been the
most successful serological test for pancreatic cancer but its
main disadvantage apart from cost has been a fairly high
false positive rate in patients with benign obstructive
jaundice, benign liver disease or benign pancreatic disease
(Haglund et al., 1986b; Piantino et al., 1986; Satake et al.,
1985), including cystic fibrosis (Roberts et al., 1986) in which
it is elevated in 87% of cases. This reflects the fact that the
CA19-9 epitope is present in normal bile (Albert et al., 1987)
and pancreatic juice (Schmiegel et al., 1985). PNA-ELLA
shows very similar overall sensitivity and specificity to
CA19-9 assay. However, there is a basic difference in their
epitope structures. PNA identifies the disaccharide galactose
1-3, N-acetyl galactosamine which is usually present as the
base carbohydrate pair on desialylated mucin side chains
whereas CA19-9 antibody recognises a complex carbohydrate
structure, sialylated N-fucopentaose II oligosaccharide. Thus
the mucin carbohydrate side chain identified by PNA lectin
is shorter and likely to be more immature than the side
chain identified by CA19-9 antibody, which is more heavily
glycosylated and sialylated.
There is an increasing tendency for tumour marker assays
to be performed using a combination of two or three
markers. This approach seems particularly logical in
pancreatic cancer where the tumour has been shown to
secrete a very large mucus glycoprotein (Ching & Rhodes,
1988) which potentially bears a large number and variety of
carbohydrate epitopes. For example the combination of
CA19-9 and DU-PAN-2 assay has recently been shown to be
more sensitive than either assay alone (Takasaki et al., 1988).
This study has shown that the combination of PNA-ELLA
and CA19-9 radioimmunoassay has a sensitivity of 85%,
specificity of 85% and positive predictive value of 68%,
results which compare very well with other more elaborate
tests such as ultrasonography or computerised tomography.
This level of specificity is, however, still not sufficiently high
for screening an asymptomatic population for a relatively
uncommon condition (even a 1% false positive rate would
result in 1,000 healthy patients undergoing further
investigation for every nine patients with pancreatic cancer,
assuming an incidence of 9 per 100,000).
The enzyme linked peanut lectin assay is cheap, easy to
perform and reproducible and its use, probably in
combination with CA19-9 radioimmunoassay should prove
helpful in the diagnosis of pancreatic cancer.
C.K.C. is an Amelie Waring research fellow of the British Digestive
Foundation.
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